Assetmark Inc. Has $131.99 Million Stake in Exelixis, Inc. $EXEL

Assetmark Inc. lifted its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 1,230.8% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 3,195,971 shares of the biotechnology company’s stock after purchasing an additional 2,955,813 shares during the quarter. Assetmark Inc.’s holdings in Exelixis were worth $131,994,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of EXEL. TriaGen Wealth Management LLC bought a new stake in shares of Exelixis during the 3rd quarter valued at about $2,024,000. BridgePort Financial Solutions LLC bought a new stake in Exelixis in the third quarter worth approximately $517,000. Candriam S.C.A. lifted its stake in Exelixis by 18.4% in the third quarter. Candriam S.C.A. now owns 696,104 shares of the biotechnology company’s stock valued at $28,749,000 after buying an additional 108,367 shares during the period. Allianz Asset Management GmbH boosted its holdings in shares of Exelixis by 153.3% during the 3rd quarter. Allianz Asset Management GmbH now owns 2,462,948 shares of the biotechnology company’s stock worth $101,720,000 after buying an additional 1,490,520 shares in the last quarter. Finally, Fox Run Management L.L.C. acquired a new stake in shares of Exelixis during the 2nd quarter worth approximately $321,000. Institutional investors and hedge funds own 85.27% of the company’s stock.

Exelixis Trading Down 0.6%

Shares of Exelixis stock opened at $42.70 on Friday. The business’s fifty day simple moving average is $43.63 and its 200 day simple moving average is $40.95. Exelixis, Inc. has a 12 month low of $32.38 and a 12 month high of $49.62. The firm has a market capitalization of $11.09 billion, a P/E ratio of 15.42, a price-to-earnings-growth ratio of 0.73 and a beta of 0.42.

Exelixis (NASDAQ:EXEL) last announced its earnings results on Tuesday, February 10th. The biotechnology company reported $0.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.20. The firm had revenue of $598.66 million during the quarter, compared to analyst estimates of $609.17 million. Exelixis had a return on equity of 36.29% and a net margin of 33.73%.The business’s revenue was up 5.6% compared to the same quarter last year. During the same period last year, the firm posted $0.55 EPS. Analysts predict that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. Citigroup downgraded shares of Exelixis from a “market outperform” rating to an “underperform” rating in a research report on Monday, January 5th. HC Wainwright upped their price objective on shares of Exelixis from $52.00 to $54.00 and gave the company a “buy” rating in a report on Thursday. Wall Street Zen raised shares of Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Sunday, December 14th. Wells Fargo & Company boosted their target price on Exelixis from $30.00 to $35.00 and gave the company an “equal weight” rating in a research report on Wednesday. Finally, Royal Bank Of Canada increased their price target on Exelixis from $45.00 to $46.00 and gave the stock a “sector perform” rating in a report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, ten have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $47.11.

More Exelixis News

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: Q4 EPS beat and shareholder returns — Exelixis reported $0.94 EPS vs. ~$0.74 consensus and repurchased $264.5M of stock, improving profitability metrics and returning capital to shareholders. Exelixis Reports Solid Earnings
• Positive Sentiment: Zanzalintinib upside — Management is positioning for a potential 2026 launch (PDUFA Dec. 3, 2026) for zanzalintinib in colorectal cancer, which the company cites as a multi‑billion dollar peak-sales opportunity and core to its franchise growth thesis. Pipeline & Franchise Strategy
• Positive Sentiment: Analyst upward moves — Royal Bank of Canada nudged its price target to $46 (sector perform), and Barclays has also raised targets recently, signaling some analyst confidence in the growth story. Analyst Note
• Neutral Sentiment: Core revenue driver — Cabometyx remains the primary revenue engine (franchise sales cited at ~$2.12B) and management guided 2026 revenue to $2.52–2.62B excluding potential zanzalintinib sales. Growth Strategy
• Neutral Sentiment: Supporting disclosure — Full earnings call transcript, presentation and analyst writeups are available for deeper due diligence. Earnings Presentation Call Transcript
• Neutral Sentiment: Short-interest data appears anomalous (reports showing 0 shares); treat as unreliable until corrected by exchanges/clearing agents.
• Negative Sentiment: Revenue miss and conservative baseline guidance — Q4 revenue ($598.7M) came in below the ~$609M consensus and 2026 guidance excludes potential zanzalintinib revenue, creating near‑term uncertainty and prompting profit-taking. Zacks Earnings Coverage
• Negative Sentiment: Mixed analyst stance — Wells Fargo raised its target to $35 but maintains an Equal Weight stance, which implies limited near‑term upside and contrasts with higher targets from other shops; this divergence contributes to volatile near-term sentiment. Wells Fargo Note

Insider Transactions at Exelixis

In other Exelixis news, EVP Patrick J. Haley sold 28,043 shares of Exelixis stock in a transaction dated Friday, November 21st. The shares were sold at an average price of $42.58, for a total value of $1,194,070.94. Following the sale, the executive vice president owned 374,029 shares of the company’s stock, valued at approximately $15,926,154.82. The trade was a 6.97% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold a total of 72,230 shares of company stock worth $3,046,923 in the last three months. Company insiders own 2.82% of the company’s stock.

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.